Skip to main content

Table 3 Correlation between PIK3CA mutation status and clinical variables

From: PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

   PIK3CA wild-type PIK3CA mutated P valuea
Pathological complete response (pCR) versus residual disease (RD) RD 95 (83%) 18 (82%) 1.000
  pCR 20 (17%) 4 (18%)  
  Unknown 2 1 -
Residual cancer burden 0 20 (22.0%) 4 (26.7%) 0.121 (0.166b)
  I 7 (7.7%) 0 (0%)  
  II 37 (40.7%) 10 (66.7%)  
  III 27 (29.7%) 1 (6.7%)  
  Unknown 26 8 -
Estrogen receptor (ER) status ER- 54 (46%) 8 (35%) 0.365
  ER+ 63 (54%) 15 (65%)  
Progesterone receptor (PR) status PR- 71 (60.7%) 11 (47,8%) 0.259
  PR+ 46 (39.3) 12 (52,2%)  
HER2 status HER2- 104 (89%) 21 (91%) 1.000
  HER2+ 13 (11%) 2 (9%)  
Grade Grade 1–2 46 (47%) 10 (56%) 0.612
  Grade 3 51 (53%) 8 (44%)  
  Unknown 20 5 -
Nodal status Negative 29 (25%) 12 (52%) 0.012
  Positive 88 (75%) 11 (48%)  
Tumor size T0 1 (1%) 1 (4%) 0.535
  T1 7 (6%) 0 (0%)  
  T2 59 (50%) 12 (52%)  
  T3 18 (15%) 3 (13%)  
  T4 32 (27%) 7 (30%)  
Ethnicity Asian 2 (2%) 1 (4%) 0.505
  Black 11 (9%) 2 (9%)  
  Hispanic 40 (34%) 10 (43%)  
  Caucasian 64 (55%) 10 (43%)  
Median age (minimum-maximum), years   50 (28–73) 52 (42–73) -
  1. aChi-square test. b P value for comparison of residual cancer burden (RCB)-0 and RCB-I versus RCB-III. PIK3CA, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide.